Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: I

77 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Ayoub, Walid	TERN201-1007	A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
Balmanoukian, Ani	C-800-01	A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer (IRB#1612)
Balmanoukian, Ani	SGN228-001	A phase 1 study of SGN-CD228A in select advanced solid tumors (IRB#138)
Balmanoukian, Ani	SGNSTNV-001	A Phase 1 Study of SGN-STNV in Advanced Solid Tumors (IRB#1148)
Basho, Reva	TAK-676-1003	TAK-676-1003: An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non Small-Cell Lung Cancer, Triple-Negative Breast Cancer, or Squamous-Cell Carcinoma of the Head and Neck that Has Progressed on Checkpoint Inhibitors (IRB#1378)
Chaux, George	STUDY00000883	Respiratory application of a novel ultraviolet light delivery device for patients infected with COVID-19: A Pilot Study
Chiu, Vi K.	831-IO-101	831-IO-101: A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors (IRB#1779)
Darrah, Justin	CRSP-ONC-001	CRSP-ONC-001: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (IRB#1154)
Darrah, Justin	GCT3013-02	GCT3013-02: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody® CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma (IRB#1087)
Fleshner, Phillip	TU100P2T4	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) protocol in Subjects Undergoing Bowel Resection.
Friedman, Oren	CAP-1002COVID-19-2	Protocol CAP-1002 in Severe COVID-19 Disease: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF INTRAVENOUS DELIVERY OF CAP-1002 IN PATIENTS WITH SEVERE COVID-19 (INSPIRE)
Gong, Jun	IIT2020-02-GONG-GLUTAPANC	IIT2020-02-Gong-GlutaPanc: Phase I trial of first-line L-glutamine with gemcitabine and nab-paclitaxel in advanced pancreatic cancer (GlutaPanc) (IRB#1113)
Gong, Jun	WO42758	WO42758: A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC) (IRB# 1565)
Gupta, Navyash	SAVVE-STUDY01-21-US	The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis (SAVVE) Study
Gutierrez, Rodolfo	IMC-C103C-101	A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer (IRB#56562)
Gutierrez, Rodolfo	TYR-219-01	A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer (IRB#907)
Hamid, Omid	212214	212214: A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (IRB#688)
Hamid, Omid	ALKS4230-001	ALKS4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors-ARTISTRY-2 (001) (IRB#0539)
Hamid, Omid	BO43328	BO43328: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA (MORPHEUS-MELANOMA) (IRB#1699)
Hamid, Omid	C4401001	C4401001: A Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07257876 in Patients with Advanced or Metastatic Tumors (IRB#1500)
Hamid, Omid	CIBI322A102	CIBI322A102 A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors. (IRB#1021)
Hamid, Omid	D8510C00001	D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295)
Hamid, Omid	ENB-003-101-MK3475-951	ENB-003-101-MK3475-951: A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (IRB#1470)
Hamid, Omid	IMC-F106C-101	IMC-F106C-101: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A 02:01-Positive Participants with Advanced PRAME-Positive Cancers (STUDY#513)
Hamid, Omid	INCA0186-101	A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1544)
Hamid, Omid	INCAGN2385-201	INCAGN2385-201: A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1), INCAGN02385 (Anti LAG-3), and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies (IRB#00685)
Hamid, Omid	LOKON003	LOKON003: A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma (IRB#525)
Hamid, Omid	MK-3475-U02-01	MK-3475-U02-01: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma: Master (KEYNOTE-U02) (IRB#595)
Hamid, Omid	MPH313-1-02	MPH313-1-02: A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors (IRB#1277)
Hamid, Omid	NC318-01	NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833)
Hamid, Omid	R6569-ONC-1933	R6569-ONC-1933: A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR mAb, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES (IRB#920)
Hamid, Omid	RTX-240-01	PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY (IRB#596)
Hamid, Omid	TWT-101	TWT-101: A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies (IRB#819)
Hendifar, Andrew	RGX-202-001	RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (IRB#55176)
Irwin, Scott	IIT2019-18-IRWIN-KETANX	IIT2019-18-IRWIN-KETANX: A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine versus Placebo for the Treatment of Anxiety in Patients with Pancreatic Cancer (IRB#1632)
Jordan, Stanley	IIT-JORDAN-2020	A Phase I/II, Double-Blind, Placebo-Controlled Study: Assessing Safety and Efficacy of Preoperative Renal Allograft Infusions of C1 Inhibitor (Berinert®) (Human) (C1INH) vs. Placebo Administration in Recipients of a Renal Allograft from Deceased High Risk Donors and its impact on Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI)
Lewis, Richard	CNS10-NPC-GDNF	Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral Sclerosis
Makkar, Rajendra	2019-06-EVOQUE	Early Feasibility Study of the Edwards EVOQUE Tricuspid Valve Replacement System
Makkar, Rajendra	ABT-CIP-10354	Cephea Early Feasibility Study
Mehmi, Inderjit	20190131	20190131 : A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors (IRB#705)
Mehmi, Inderjit	DAY101-102	A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations (IRB#1473)
Mehmi, Inderjit	FHD-286-C-001	A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma (IRB#1365)
Mehmi, Inderjit	SRF617-101	SRF617: A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors (IRB#811)
Mehmi, Inderjit	TBX-3400-001	TBX-3400-001: A Phase 1 Multi-Center Dose-Escalation Study of The Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (IRB#1000)
Mehmi, Inderjit	TBX-3400-003	TBX-3400-003: A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects with Solid Malignant Tumors Resistant or Refractory to Standard Therapies (IRB#1675)
Melmed, Gil	STUDY00000256	A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients with Active Crohn's Disease.
Merin, Noah	IIT2017-05-MERIN-BLINHMCT	IIT2017-05-Merin-BlinHMCT: Blinatumomab plus HLA Mismatched Cellular Therapy (HMCT) for Relapsed Refractory CD19+ ALL (IRB#52176)
Mita, Alain	61186372NSC1003	61186372NSC1003: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies (IRB#1175)
Mita, Alain	ASTX029-01	ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467)
Mita, Alain	ASTX295-01	ASTX295-01: Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors (IRB#016)
Mita, Alain	BNT411-01	BNT411-01: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) (IRB#578)
Mita, Alain	IIT2021-04-MITA-DZ002	IIT2021-04-Mita-DZ002: A Phase 1 Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients with Advanced Solid Malignancies or Lymphoma (IRB#01430)
Mita, Alain	Q702-ONC-P1-US001	Q702-ONC-P1-US001: A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors (IRB#1380)
Mita, Monica	C4551001	C4551001: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (IRB#1043)
Mita, Monica	GEN-602-CT-101	GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184)
Mita, Monica	HMBD-002-V4C26-01	HMBD-002-V4C26-01: A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies (IRB#1841)
Mita, Monica	INCB106385-102	INCB106385-102: A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1094)
Mita, Monica	JTX-8064-101	JTX-8064-101:Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies (IRB#1498)
Mita, Monica	LNS-101	LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer (IRB#315)
Mita, Monica	M16-573	M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid tumors (IRB#24)
Mita, Monica	MINNELIDE101	MINNELIDE101: A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Capsules given alone or in combination with Protein-Bound Paclitaxel in patients with Advanced Solid Tumors (IRB#49784)
Mita, Monica	MT-5111-001	MT-5111-001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Monica	SQZ-PBMC-HPV-101	SQZ-PBMC-HPV-101: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (IRB#577)
Mita, Monica	SY-5609-101	SY-5609-101: A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors (IRB#1358)
Mita, Monica	TH1902-CTR-001	TH1902-CTR-001:A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer (IRB#1343)
Reckamp, Karen	73841937NSC1001	73841937NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer (IRB#910)
Reckamp, Karen	BLU-945-1101	BLU-945-1101: A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer (IRB#1446)
Reinisch, John	3DBIO12A2020	A Multicenter, Single Arm, Prospective, Open-Label, Staged Study of the Safety and Efficacy of the AuriNovo Construct for Auricular Reconstruction in Subjects with Unilateral Microtia
Rimel, Bobbie Jo	MER-XMT-1536-1	MER-XMT-1536-1/GOG-3048: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (IRB#919)
Rudnick, Jeremy	APL-101-01	APL-101-01: Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumor (IRB#898)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)
Siegel, Robert	CT-G20-12	A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-G20 in Subjects with Hypertrophic Obstructive Cardiomyopathy
Vescio, Robert	ION251-CS1	ION251-CS1: A Phase I Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma (IRB#972)
Wentzel, Kristopher	9801-CL-0101	9801-CL-0101: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced/Metastatic Solid Tumors (IRB#57758)
Wentzel, Kristopher	XL092-001	XL092-001: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors (IRB#1111)
Zumsteg, Zachary	NRG-GU007	NRG-GU007: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (IRB#184)